Verastem

Verastem Inventory

The Inventory of Verastem (VSTM) as of Nov 22, 2026 is 1.83 M USD.

Inventory

1.83 MUSD

Last updated:

Inventory of Verastem is 2025 1.83 M USD. Inventory of Verastem was 2024 0.00 USD. It decreases by % higher compared to the previous year.

The Verastem Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
327,000.00 USD
Jan 1, 2019
3.10 M USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
-100.77 M USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
1.83 M USD
The Verastem Inventory history
YEARInventoryYoY
1.83 MUSD—
0.00USD-100.00%
-100.77 MUSD—
0.00USD-100.00%
3.10 MUSD+846.79%
327,000.00USD—
0.00USD—
0.00USD-100.00%
-154,000.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Verastem Stock analysis

What does Verastem do? Verastem Oncology develops and commercializes oncology drugs to improve cancer patient survival and quality of life. The company focuses on defactinib, an oral small molecule inhibitor of FAK and PYK2, and VS-6766, a RAF/MEK pathway inhibitor. Defactinib is being evaluated for combination therapy in solid tumors, while VS-6766 blocks MEK kinase activity and RAF phosphorylation. Verastem conducts clinical trials for cancers with limited treatment options including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer, and pancreatic cancer. The company markets and develops these products for healthcare providers and patients in the oncology segment. Verastem Oncology targets cancer patients requiring new treatment options, particularly in underserved areas like pancreatic cancer and mesothelioma. Its products are designed to address unmet medical needs in oncology through targeted therapies. Verastem generates revenue through the commercialization of defactinib and VS-6766 once approved. The company's business model relies on developing drugs for cancer treatment, with clinical trials focused on improving outcomes for patients with limited therapeutic options. Revenue streams come from product sales and potential partnerships for drug development and commercialization. Verastem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Verastem stock

Inventory of Verastem is 1.83 M USD in 2025.

On Eulerpool you can find the complete historical development of Inventory Verastem since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Verastem historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Verastem

All Key Metrics — Verastem